Abstract
Is Treatment Heterogeneity an <scp>A</scp>chilles' Heel for Comparative Effectiveness Research?
Highlights
The American Recovery and Reinvestment Act (ARRA) included $1.1 billion to support comparative effectiveness research (CER)
A review of lessons learned from ALLHAT concluded that the landmark trial demonstrated the value of comparative effectiveness research, but emphasized that studies based on population averages risk overlooking the needs of individual patients
Others have argued that CER is “rigged against new drugs” and “designed to eliminate the individual differences that are at the heart of the generation of personalized medicines” [2]
Summary
The American Recovery and Reinvestment Act (ARRA) included $1.1 billion to support comparative effectiveness research (CER). Proponents argue that knowing more about the comparative effectiveness of different treatments will empower decision makers to choose the safest and most effective options, increasing the value of the healthcare dollar.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
